Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-26-8 Ubunyulu >99.0% (HPLC) Nintedanib Esylate Intermediate Factory

Inkcazelo emfutshane:

Igama leKhemikhali: Methyl 2-Oxoindoline-6-Carboxylate

CAS: 14192-26-8

Ubunyulu: >99.0% (HPLC)

Imbonakalo: Mthubi oKhanyayo ukuya kumgubo oBrown

I-Intermediate ye-Nintedanib Esylate (i-CAS: 656247-18-6) kunyango lwe-non-small cell lung cancer kunye ne-idiopathic pulmonary fibrosis (IPF)

Umgangatho ophezulu, iMveliso yoRhwebo

E-Mail: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili kunye nomthengisi weMethyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) enomgangatho ophezulu, imveliso yorhwebo.

Iipropati zeMichiza:

Igama leMchiza	I-Methyl 2-Oxoindoline-6-Carboxylate
Izithethantonye	I-2-Oxoindoline-6-Carboxylic Acid Methyl Ester;I-Methyl Oxindole-6-Carboxylate
Inombolo yeCAS	14192-26-8
Inombolo yeCAT	RF-PI1524
Ubume beStokhwe	Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli	C10H9NO3
Ubunzima beMolekyuli	191.19
Indawo yokunyibilika	184.0 ~ 190.0℃
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Umthubi oKhanyayo ukuya kumgubo oBrown
I-1 H NMR Spectrum	Ukungqinelana Nolwakhiwo
Ubunyulu / Indlela yokuHlalutya	>99.0% (HPLC)
Ilahleko ekomisweni	<1.00%
Ukungcola ngokupheleleyo	<1.00%
Umgangatho woVavanyo	Umgangatho woShishino
Ukusetyenziswa	Umbindi weNintedanib Esylate (CAS: 656247-18-6)

I-Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) Indlela yokwenziwa

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma.

Izinto eziluncedo:

FAQ:

Isicelo:

I-Methyl 2-Oxoindoline-6-Carboxylate (i-CAS: 14192-26-8) yindawo ephakathi esetyenziselwa ukulungiselela i-Nintedanib Esylate (CAS: 656247-18-6).I-Nintedanib Esylate inamandla, i-oral triple angiokinase inhibitor ephuhliswe nguBoehringer Ingelheim ejolise kwiindlela zeproangiogenic kunye ne-pro-fibrotic ezidityaniswe yi-vascular endothelial growth factor receptor, i-fibroblast growth factor receptor kunye ne-plateletderived growth factor receptor iintsapho, kunye ne-Src kunye ne-Flt-3 kinases.I-Nintedanib Esylate ivunyiwe kunyango lwe-idiopathic pulmonary fibrosis (IPF), imeko apho imiphunga iba namanxeba ngokuqhubekayo ngokuhamba kwexesha, yi-US FDA ngo-Okthobha ka-2014 kunye ne-EMA ngoJanuwari 2015. I-FDA inike i-nintedanib esylate ngokukhawuleza , uphononongo oluphambili, imveliso yeenkedama, kunye nokutyunjwa kwempumelelo.Ikwaphunyezwe yi-EMA ngoNovemba ka-2014 kunyango lomhlaza wemiphunga ongeyonxalenye encinci kunye ne-docetaxel emva kwechemotherapy yodidi lokuqala.